Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 13 Apr 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 May 2026, providing investors with the latest insights into its performance and outlook.

Surging to a new all-time high of Rs 2,548 on 6 May 2026, Fredun Pharmaceuticals Ltd has demonstrated remarkable price momentum, extending gains over four consecutive sessions to deliver a near 20% rally. This milestone caps a spectacular 257.45% return over the past year, vastly outperforming the Sensex’s decline of 4.16% during the same period.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching its all-time high price of Rs. 2,548 on 06 May 2026, marking a remarkable journey of sustained growth and strong market performance in the Pharmaceuticals & Biotechnology sector.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd has reached a new 52-week high of Rs 2471 on 05 May 2026, marking a remarkable rally of 242.02% over the past year. This milestone is underpinned by a confluence of strong technical indicators and sustained price momentum, even as the broader market trades cautiously.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching its all-time high price of Rs.2,471 on 05 May 2026, marking a remarkable achievement in the company’s stock market journey. This surge reflects the company’s robust financial performance and sustained growth over recent years.

Fredun Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting a significant change in price attractiveness. Despite this, the company’s robust financial metrics and strong market performance continue to underpin its Buy rating, signalling confidence in its growth prospects within the Pharmaceuticals & Biotechnology sector.

A 244.83% stock return in one year. An 81.2% growth in net profit over the same period. The gap between those two numbers — roughly 163 percentage points — is driven largely by the market's willingness to pay more for each rupee of Fredun Pharmaceuticals Ltd's earnings. That premium expansion is the defining feature of this multibagger rally.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a new 52-week high of Rs 2424 on 04 May 2026, marking a remarkable rally from its low of Rs 666 just a year ago. This milestone underscores a powerful momentum driven by a confluence of technical indicators aligning in favour of the stock’s upward trajectory.

Extending its recent rally, Fredun Pharmaceuticals Ltd surged to a fresh all-time high of Rs 2,424 on 04 May 2026, outperforming the broader Sensex by a wide margin and marking a significant milestone in its price journey.

Surging past its previous peaks, Fredun Pharmaceuticals Ltd touched a new 52-week and all-time high of Rs 2,278.85 on 30 Apr 2026, marking a remarkable rally from its 52-week low of Rs 666. This milestone caps a year of extraordinary price momentum, with the stock delivering a staggering 215.44% return compared to the Sensex’s decline of 3.84% over the same period.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs. 2,235 on 30 April 2026, reflecting its robust performance and sustained growth in the Pharmaceuticals & Biotechnology sector.

Surging to an all-time high of Rs 2200 on 28 Apr 2026, Fredun Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector by 7.28% today and marking a 209.71% gain over the past year. This milestone reflects a confluence of strong technical signals and sustained earnings growth that have propelled the stock well beyond its 52-week low of Rs 655.2.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs 2,176.05 on 28 April 2026, reflecting a strong upward trajectory driven by consistent financial growth and market outperformance.

Fredun Pharmaceuticals Ltd is rated Buy by MarketsMOJO, with this rating last updated on 13 April 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 25 April 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Surging to a new all-time high of Rs 2149.9 on 24 Jun 2026, Fredun Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a bearish backdrop for the Sensex. This milestone caps a year-long rally that has more than tripled the stock price from its 52-week low of Rs 655.2, underscoring the strength of technical signals driving this advance.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching its all-time high price of ₹2,145 on 24 April 2026, reflecting a remarkable journey of sustained growth and robust financial performance within the Pharmaceuticals & Biotechnology sector.

Fredun Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs. 2,141 on 22 April 2026, marking a remarkable achievement in the company’s market journey and reflecting its robust financial performance and sustained growth.